An Overview on Diffuse Large B-Cell Lymphoma Models: Towards a Functional Genomics Approach

Natalia Yanguas-Casás 1,*, Lucia Pedrosa 1,2, Ismael Fernández-Miranda 1,2 and Margarita Sánchez-Beato 1,3,*

1 Lymphoma Research Group, Medical Oncology Department, Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana (IDIPHISA), C/Joaquín Rodrigo 2, Majadahonda, 28222 Madrid, Spain; lpedrosa@idiphim.org (L.P.); ifernandez@idiphim.org (I.F.-M.)
2 PhD Programme in Molecular Biosciences, Doctorate School, Universidad Autónoma de Madrid, 28049 Madrid, Spain
3 Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 28029 Madrid, Spain
* Correspondence: nyanguas@idiphim.org (N.Y.-C.); msbeato@idiphim.org (M.S.-B.)

Simple Summary: Lymphoma research is a paradigm of integrating basic and applied research within the fields of molecular marker-based diagnosis and therapy. Clinical, phenotypic, and genetic data are currently used to predict which patients could benefit from standard treatment. However, alternative therapies for patients at higher risk from refractoriness or relapse are usually empirically proposed, based on trial and error, without considering the genetic complexity of aggressive B-cell lymphomas. This is primarily due to the intricate mosaic of genetic and epigenetic alterations in lymphomas, which are an obstacle to the prediction of which drug will work for any given patient. Matching a patient’s genes to drug sensitivity by directly testing live tissues comprises the “precision medicine” concept. However, in the case of lymphomas, this concept should be expanded beyond genomics, eventually providing better treatment options for patients in need of alternative therapeutic approaches. We provide an overview of the most recent findings in diffuse large B-cell lymphomas, from the classic functional models used to study tumor biology and the response to experimental treatments using cell lines and mouse models, to the most recent approaches with spheroid/organoid models. We also discuss their potential relevance and applicability to personalized medicine.

Abstract: Lymphoma research is a paradigm of integrating basic and clinical research within the fields of diagnosis and therapy. Clinical, phenotypic, and genetic data are currently used to predict which patients could benefit from standard treatment. However, alternative therapies for patients at higher risk from refractoriness or relapse are usually empirically proposed, based on trial and error, without considering the genetic complexity of aggressive B-cell lymphomas. This is primarily due to the intricate mosaic of genetic and epigenetic alterations in lymphomas, which are an obstacle to the prediction of which drug will work for any given patient. Matching a patient’s genes to drug sensitivity by directly testing live tissues comprises the “precision medicine” concept. However, in the case of lymphomas, this concept should be expanded beyond genomics, eventually providing better treatment options for patients in need of alternative therapeutic approaches. We provide an overview of the most recent findings in diffuse large B-cell lymphomas, from the classic functional models used to study tumor biology and the response to experimental treatments using cell lines and mouse models, to the most recent approaches with spheroid/organoid models. We also discuss their potential relevance and applicability to daily clinical practice.

Keywords: B-cell lymphoma; diffuse large B-cell lymphoma; genomics; functional model; cell lines; murine models; gene editing; organoid/spheroid; therapy; cancer

1. Unraveling Aggressive B-Cell Lymphomas: The Elusive Link between Genomics and Personalized Treatment

Lymphoma research is a paradigm of the integration of basic and applied research within the fields of molecular-marker-based diagnosis and therapy. Basic research on lymphomas has deepened our knowledge of cancer mechanisms, while helping to elucidate how aging, infection, the immune system, and other genetic and environmental factors might account for the increasing incidence of this disease in western countries. The rapid rise of high-throughput technologies in recent years has led to a growing number of...
genomic studies that emphasize and characterize the high degree of genomic heterogeneity in lymphomas. Genetic classification and other phenotypic and clinical data are currently used to predict which patients could benefit from standard treatment. However, new therapies that could be of use to patients at higher risk from refractoriness or relapse have yet to be applied in daily clinical practice. Indeed, the proposal of alternative treatments for diffuse large B-cell lymphoma (DLBCL) patients who do not respond to standard immunotherapeutic regimens (up to 30–40%) is mostly empirical, based on trial and error, and does not consider their genetic complexity. This is primarily due to the intricate mosaic of genetic and epigenetic alterations in lymphomas, and the unpredictable effects on their phenotype, which make it difficult to foresee which drug will work for any given patient. Epigenetic processes, such as methylation and demethylation, are responsible for the dynamic plasticity of B-cells and affect tumor behavior (for a recent review, see [1]). Interestingly, many of the genetic mutations that occur in DLBCL affect genes involved in chromatin remodeling (EZH2, CREBBP, KMT2D, etc.) and other epigenetics functions such as DNA methylation (TET2).

Patient treatment based on genomic analysis alone is not straightforward. Matching a patient’s genes or a specific genetic signature to drug sensitivity by directly testing live tissues is the basis of the concept of precision medicine. However, in the case of lymphomas, we need to expand this concept beyond genomics to eventually provide better treatment options for patients in need of alternative therapeutic approaches. Functional assays could help fill this gap. Established models, such as those of tumor cell lines and mice, do not completely capture the complex genetic and epigenetic landscape that each patient presents, and, therefore, the translation of findings from these models to the clinic remains inefficient. Three-dimensional (3D) models, such as organoids, which can be generated from several cell types and reproduce the interactions of a patient’s immune system with their tumor, will be a promising tool in personalized medicine in the near future.

2. Diffuse Large B-Cell Lymphomas: Clinically Unresolved Genomic Complexity
2.1. Diffuse Large B-Cell Lymphoma: A Traditional Overview

DLBCL is an aggressive and heterogeneous disease with a variable clinical outcome. It is the most common non-Hodgkin lymphoma (NHL) subtype, with 3.13 and 5.6 new cases diagnosed per 100,000 inhabitants per year in Europe [2] and the United States [3], respectively. DLBCL is subdivided into morphological variants, molecular subtypes and different clinical entities (for a recent review, see [4]). The cases classified as DLBCL not otherwise specified (DLBCL-NOS) are biologically heterogeneous and the current classification for this lymphoma is based on its cell of origin (COO). Two subtypes are recognized based on the gene expression profile: activated B-cell (ABC) and germinal center B-cell (GCB) DLBCL [5,6]. Around 10–15% of cases cannot be classified as either of these subtypes and, therefore, remain unclassified. This classification is of prognostic value, with ABC-DLBCL being associated with poorer clinical outcome.

The most recent revision of lymphoid neoplasms by the WHO [7,8] recognized a more aggressive, high-grade B-cell lymphoma subtype with a worse prognosis, the ‘double-hit’/‘triple-hit’ (DH/TH) lymphoma, which is characterized by MYC rearrangements that are associated with BCL2 and/or BCL6 rearrangements. Lymphomas that co-express the MYC and BCL2 proteins, known as double-expressor lymphomas, are relatively frequent, and have a worse prognosis than other DLBCL-NOS, although their behavior is not as aggressive as that of the DH/TH lymphomas [9].

In recent years, several studies using massive sequencing analysis have helped to define the genetic landscape of DLBCL by identifying many genetic alterations. Primarily, DLBCL has alterations in genes involved in B-cell differentiation pathways, such as chromosomal rearrangements of the BCL6 locus and mutations/deletions in PRDM1 [10–12] and IRF8 [13,14] and BCR/NF-κB signaling, such as CD79B/A, BCL10, TNFAIP3, and CARD11 [11,12,14–20]. Other relevant pathways are also affected, such as the Toll-like receptor pathway, with mutations in MYD88 and, less frequently, in TRAF6 [11,12,14,17–21]; the
p53 and DNA damage pathway, with deletions/mutations in TP53 and UBE2A [11,14,17,19,22], and methylation/deletions of CDKN2A [23]; and the PI3K/AKT pathway with mutations in PTEN and PIK3CA [24]. Other genes that are frequently or significantly altered are MYC (which modulates many cellular functions, such as DNA replication and cell proliferation), BCL2 (cell apoptosis), NOTCH1, NOTCH2, and DTX1 (cell differentiation), GNA13 (cell migration), CD58 and B2M (immune evasion), PIM1, BTG1, and CCND3 (cell cycle), and the epigenetic regulators EZH2, HIST1H1E, HIST1H1C, KMT2D, CREBBP, and EP300 [11,12,14,17–20,25–30] (Figure 1).

Figure 1. Diffuse large B-cell lymphoma complexity: untangling the networks underlying genetic subtypes. Schematic view of the most relevant genetic events in B-cell physiology pathways for each genetic subtype (GS) highlighted in purple (MCD), light blue (BN2), yellow (EZB), green (N1), or red (ST2), as described in the figure key. Mutations in CD79A and CD79B and SYK lead to chronic activation of the B-cell receptor (BCR; of special importance in the MCD GS), which triggers the activation of SYK, BTK, and PKC promoting the formation of the CARD11-BCL10-MALT1 complex. Mutations in genes that encode all the components in this complex can be identified in a subset of DLBCLs and are especially relevant for the BN2 GS. Mutations in genes that encode MYD88, IRAK1, and IRAK4 activate Toll-like receptor (TLR) signaling, which is further promoted by alterations in positive regulators downstream TLR, such as TRAF6. Alterations in Notch signaling, binding of CD27 to CD70, and BCR activation also lead to abnormal activation of PI3K-AKT-mTOR pathway, which also presents genetic alterations in this disorder. Most of these pathways converge in the activation of IKK and downstream NF-κB signaling, promoting lymphomagenesis. Tumor cell survival is boosted by alterations in the BLC2 and BCL6 axis, TP53, and imbalances in cytokine related pathways: interleukins (IL), interferon gamma (IFNγ), or tumor necrosis factor (TNF), which overall lead to increased survival and decreased apoptosis in these cells. Alterations at the nuclear level are also common in all genetic subtypes (except for the N1 subtype), and involve p53, DNA damage pathway, epigenetic regulators, and other components involved in proliferation and survival cell processes. Currently, there are targeted therapies against several components downstream these pathways (tagged with a pill icon). Activating genetic events are highlighted with a star, while those involving inactivation are flagged with a hexagon.

For some genes, the mutation rate differs depending on the COO subtype. ABC-DLBCLs have a high frequency of alterations in MYD88 (MYD88L265P occurs almost exclusively in ABC-DLBCL) PRDM1, CD79B, BCL10, and BCL6 rearrangements [26,28,30]. GCB-DLBCLs have a better prognosis and frequently feature mutations in BCL2, GNA13, TNFSR14, EZH2, CREBBP, and BCL2 rearrangements [26,28,30].
Around 30% of DLBCL cases show rearrangements of the 3q27 region, involving BCL6, most commonly in the ABC subtype. BCL2 rearrangements (t(14;18), a hallmark of follicular lymphoma), have been detected in 20–30% of DLBCL cases, usually in those of GCB, and the MYC rearrangement is observed in 8–15% of cases [8]. When MYC translocation occurs simultaneously with BCL2 and/or BCL6, the cases are classified as DH/TH high-grade B-cell lymphoma, as mentioned previously [28,30].

2.2. Advances in DLBCL Genomics: Genetic Signature Helps Design Tailored Therapies

In recent years, new DLBCL genetic classifications have emerged based on specific genetic alterations defining different subtypes. In 2017, Reddy et al. presented a multivariate model using gene expression data and COO classification in combination with genetic alterations to classify patients into three risk groups with different survival outcomes [29]. A year later, Schmitz et al. [28] identified four genetic profiles—MCD, BN2, N1, and EZB—based on mutational and translocation data (Table 1). These were subsequently refined by the addition of two subtypes: ST2 and A53 [31]. MCD was characterized by mutations in MYD88L265P and CD79B, while N1 presented mutations in NOTCH1. In both subtypes, most cases were ABC-DLBCL, and had a worse prognosis than BN2, based on BCL6 fusions and NOTCH2 mutations, and EZB, which was characterized by BCL2 translocations and mutations in the EZH2 gene [28]. The ST2 subtype was characterized by recurrent mutations in SGK1 and TET2. Most cases were GCB-DLBCL and had a better survival. The A53 subtype comprised aneuploidy cases with mutations and deletions in TP53, with a worse prognosis among ABC-DLBCLs [31]. Another important study, by Chapuy et al. [32], defined five subtypes, including two ABC-DLBCL groups, one with lower risk and a possible marginal zone origin (C1, with BCL6 translocations and mutations in NOTCH2), and the other a high-risk group (C5) featuring a high frequency of cases with mutations in MYD88, CD79B, and PIM1; they also described two distinct subsets of GCB-DLBCLs with favorable (C4) and poor outcomes (C3), and an ABC/GCB-independent group (C2) with biallelic inactivation of TP53, CDKN2A loss, and associated genomic instability [32]. Similar results from a large real-world population-based patient cohort in which MYD88 (similar to MCD) and NOTCH2 (similar to BN2) subtypes had a worse prognosis than BCL2 (EZB), SOCS1/SK1, and TET2/SK1 subtypes, which, together, could be considered similar to ST2 [33] (Table 1). More recently, another study by Pedrosa et al. [34] classified samples in MCD2-S (MYD88, CD79B, PIM1, PIM2, PRDM1, BTG1, and CD58), BN2-S (BCL6 fusion, NOTCH2, BCL10, TNFAIP3, UBE2A, CD70, CCND3, and DTX1), N12-S (NOTCH1), EZB2-S (BCL2 fusion and mutation, EZH2, CREBBP, TNFRSF14, KMT2D IRF8, and EP300), and ST22-S (SOCS1, SK1, TET2, and STAT3) with a two-step classifier based on the studies by Schmitz et al., Chapuy et al., and Lacy et al. [28,32,33]. Furthermore, the Lacy cohort showed a strong consensus across three classification strategies [34,35], reinforcing the high degree of reproducibility of these subtypes.

Knowledge of these alterations may allow for the selection of better treatments than the standard rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP), based on the patient’s genetic background. Furthermore, it may prompt the development of novel agents or strategies targeting selected combinations of genes and pathways that synergistically affect the currently available drugs. These target survival pathways are driven by specific genetic and epigenetic events, such as BCR signaling, of which BTK, PI3K, and mTOR inhibitors stand out, and other agents targeting epigenetic modifiers, apoptosis, and the immune system regulator or the NF-κB pathway. To date, despite the arrival of new agents in the last decade, the actual treatment of DLBCL has changed little since the introduction of immunochemotherapy [26,36,37], and further effort is needed if precision medicine is to be successfully applied in the treatment of this pathology.
Table 1. DLBCL genomics: the genetic signature helps predict patient outcome. Comparison of the newly proposed genetic subtypes in DLBCL. The names of the genetic subtypes proposed by each group are highlighted in bold. COO: cell of origin; ABC: activated B-cell like; GCB: germinal center B-cell like; amp: amplification; transl: translocation.

| COO and Patient Outcome | COO and Patient Outcome |
|-------------------------|-------------------------|
| Wright and Schmitz [28,31] | Chapuy [32] |
| MCD | C5 |
| MYD88 L265P, CD79B, PIM1, CDKN2A | MYD88 L265P, CD79B, PIM1, PRMD1, ETV6 |
| NOTCH2, BCL6 transl., SPEN, TNFAIP3, CD70, UBE2A, BCL10, CCND3 | NOTCH2, BCL6 transl., SPEN, TNFAIP3, CD70, BCL10 |
| EZB | C3 |
| EZH2, BCL2, CREBBP, EP300, IRF8, MEF2B, GNA13, KMT2D, REL amp. | EZH2, BCL2, CREBBP, IRF8, MEF2B, KMT2D |
| N1 | NEC |
| NOTCH1 | NOTCH1, REL amp., TP53 |
| A53 | C2 |
| TP53, aneuploidy | TP53, REL, CDKN2A loss, aneuploidy |
| ST2 | C4 |
| SOCS1/SGK1–TET2/SGK1 | SOCS1, TET2, SGK1 |
| SOCS1, TET2, SGK1, HIST1H1E, NFKBIE, BRAF, CD83 | SOCS1, TET2, SGK1, STAT3 |

| COO and Patient Outcome | COO and Patient Outcome |
|-------------------------|-------------------------|
| Lacy [33] | Pedrosa [34] |
| MCD | MYD88 |
| MYD88 L265P, CD79B, PIM1, ETV6, CDKN2A | MYD88, CD79B, PIM1, PRMD1, PIM2, BTG1 |
| NOTCH2, BCL6 transl., TNFAIP3, CD70, BCL10, UBE2A, CCND3, DTX1 | NOTCH2, BCL6 transl., TNFAIP3, CD70, BCL10, UBE2A, CCND3 |
| EZB | BCL2 |
| EZH2, BCL2, CREBBP, IRF8, MEF2B, GNA13, KMT2D | EZH2, BCL2, CREBBP, IRF8, MEF2B, KMT2D |
| N1 | NEC |
| NOTCH1 | NOTCH1, REL amp., TP53 |
| A53 | C2 |
| TP53, aneuploidy | TP53, REL, CDKN2A loss, aneuploidy |
| ST2 | C4 |
| SOCS1/SGK1–TET2/SGK1 | SOCS1, TET2, SGK1 |
| SOCS1, TET2, SGK1, HIST1H1E, NFKBIE, BRAF, CD83 | SOCS1, TET2, SGK1, STAT3 |

| COO and Patient Outcome | COO and Patient Outcome |
|-------------------------|-------------------------|
| COO and Patient Outcome | COO and Patient Outcome |
| MCD | MCD2-S |
| MYD88 L265P, CD79B, PIM1, PRMD1, ETV6 | MYD88, CD79B, PIM1, PRMD1, PIM2, BTG1 |
| NOTCH2, BCL6 transl., TNFAIP3, CD70, BCL10, UBE2A, CCND3, DTX1 | NOTCH2, BCL6 transl., TNFAIP3, CD70, BCL10, UBE2A, CCND3 |
| EZB | BCL2 |
| EZH2, BCL2, CREBBP, IRF8, MEF2B, KMT2D | EZH2, BCL2, CREBBP, IRF8, MEF2B, KMT2D |
| N1 | NEC |
| NOTCH1 | NOTCH1, REL amp., TP53 |
| A53 | C2 |
| TP53, aneuploidy | TP53, REL, CDKN2A loss, aneuploidy |
| ST2 | C4 |
| SOCS1/SGK1–TET2/SGK1 | SOCS1, TET2, SGK1 |
| SOCS1, TET2, SGK1, HIST1H1E, NFKBIE, BRAF, CD83 | SOCS1, TET2, SGK1, STAT3 |

| COO and Patient Outcome | COO and Patient Outcome |
|-------------------------|-------------------------|
| COO and Patient Outcome | COO and Patient Outcome |
| COO and Patient Outcome | COO and Patient Outcome |

*Mutation and translocation.

2.3. Friend or Foe: The DLBCL Microenvironment

Despite the intrinsic relevance of genetic aberrations within lymphoma cells, DLBCL complexity comprises more than genetic alterations in the tumoral cells. DLBCL cell survival and physiology depend on their interactions with the non-malignant cells and stromal elements, which constitute the tumor microenvironment (TME). The DLBCL TME involves the interactions of lymphoma cells with host immune cells, including natural killer (NK) cells (±20% of total cell content), dendritic cells (DCs) (±15%), M2-type macrophages (±15%), CD4+ T cells (±10%), and CD8+ T cells (<5%) [38]. Significantly, TME composition and its highly heterogeneous interactions with neoplastic cells determine DLBCL pathogenesis and progression [39].

Tumor cells account for 60–80% of the cell content in DLBCL. The acquired genetic mutations render tumor cells relatively independent of survival and proliferation signals from their microenvironment [40]. Regardless of this effaced TME composition pattern, it has an important impact on DLBCL patients’ survival, therapy response and disease progression or relapse. Interestingly, a recent work has described four major DLBCL microenvironment categories associated with distinct biological aberrations and clinical behavior [41]. Indeed, TME is of predictive importance in DLBCL prognosis and has been linked to resistance to chemotherapy [24,38,42]. This prompted the development of drugs targeting TME composition and the blockade of cellular interactions with dissimilar results in clinical trials. Therapeutic blockade of CD47, in combination with rituximab, showed promising response rates in DLBCL patients, while the PD-1 blockade response fell short (for a review, see [43]). On the other hand, the immune modulator lenalidomide has shown
promising results in monotherapy and in combination with R-CHOP regimens, especially in elderly ABC-DLBCL patients [40].

In conclusion, lymphomas arise within a complex microenvironment and are characterized by a considerable genetic heterogeneity. Therefore, the ideal DLBCL model should replicate both aspects, and the clinical heterogeneity of the pathology.

3. Functional Models for B-Cell Lymphoma Research

From its outset, lymphoma research has relied on a wide variety of models, from cell monolayers to whole-organism studies (predominantly mice). Over the years, advances in gene-editing techniques, mouse models, and the genesis of three-dimensional (3D) in vitro models have led to new approaches to the study of DLBCL biology and therapy responses in a more physiological environment. The generation of reliable models approximating human disease offers the potential to apply the obtained results in daily clinical practice.

3.1. Gene Editing of Lymphoma Cells

The current gene-editing techniques include DNA base editors and RNA-programmable clustered regularly interspaced short palindromic repeats (CRISPR)-associated (Cas) nucleases [44,45]. Gene editing with these systems is effective in cell lines, human samples, and murine models [46–48]. Both strategies allow for the generation of accurate lymphoma models that reproduce or revert the mutations identified by massive sequencing, to study their relevance to tumor behavior and drug response [46,47]. Moreover, synthetically engineered DLBCL models, generated immediately by the directed mutations in human cell lines, or by their combination with mice of a specific genetic background, have enabled co-operating genetic alterations to be studied [46,48], such as FOXP1 silencing, BCR pathway expression or silencing, the co-expression of BCL2/MYC or BCL2/BCL6, and the expression of GC-DLBCL or ABC-DLBCL-related genes [29,49,50].

Beyond the insertion of specific mutations in a certain region of interest, the CRISPR-Cas9 system was adapted for functional genomic screening in DLBCL cell lines. Unbiased high-throughput CRISPR-Cas9 knockout screenings of DLBCL cell lines prompted the study of the functional impact of potential genetic drivers of DLBCL, previously identified by integrative analysis of whole-exome and transcriptome sequencing [29,51].

Therefore, gene editing is a useful tool for investigating genetic and functional drivers, and tumor dynamics, in DLBCL. However, there are hurdles to overcome before gene editing can be applied in a therapeutic context, such as ensuring a higher base-editing efficiency with minimal off-target effects, establishing a way of delivering the gene-editing system in a target organ with a high degree of correction, and it being possible to edit 100% of the tumor cells. Cancer is not a monogenic disease, and multiple somatic genetic alterations are involved. However, CRISPR-Cas9 has shown promising results in preclinical studies involving immunotherapy with CAR T-cells, indicating its therapeutic potential [52].

3.2. The Rise of Drug Screening: Mission Pathways

Cancer research has largely involved cell lines and 2D cell culture (Figure 2A), as they provide a robust and reproducible model system [53–55]. The universalization of massive parallel sequencing has facilitated the analysis of a large number of cancer model collections, such as the Cancer Cell Line Encyclopedia (CCLE), which includes some hematological cancer-derived cell lines [56]. However, limitations of the coverage of the hematological oncology spectrum in general collections prompted the development of the LL-100 panel, which covers more than 20 human leukemia and lymphoma entities, including DLBCL (ABC- and GC-DLBCL) [57]. The association of the knowledge emerging from the cell-line panels and the genetic studies of patient-derived lymphoma samples [31] has enabled the identification of potential therapeutic targets.
B-cell-lymphoma-derived cell lines have been widely used in the study of antitumor drugs. On the one hand, some strategies seek the functional confirmation of drug activity in these cell lines through the integration of omics-analysis with the use of isoform-specific inhibitors and/or small hairpin RNA (shRNA) or CRISPR-Cas9-mediated knockout [58–61]. On the other hand, other drug-screening approaches target lymphoma survival signaling pathways and critical alterations in DLBCL, such as those described below.

The B-cell receptor (BCR) pathway, key to B-cell survival, is an especially relevant therapeutic target, as its expression is restricted to B-cells, revealing potential pharmacological agents specific to these cells. Importantly, BCR signaling is chronically active in ABC-DLBCLs, with the consequent canonical NF-κB pathway activation [5,6,62]. Ibrutinib, a Bruton’s tyrosine kinase (BTK) inhibitor that blocks BCR-dependent NF-κB activation, is one of the candidates for tailored medicine for DLBCL patients, due to its strong effects in
DLBCL-derived cell lines. In vitro approaches revealed a selective toxicity in ABC-DLBCL cell lines with mutations in CD79A/CD79B and MYD88L265 [15,63], suggesting a potential targeted therapy for ABC-DLBCL or the newly proposed genetic subtype MCD-DLBCL. However, clinical trials have shown that BTK inhibitors have a limited effect on DLBCL compared to other lymphoma subtypes [64].

NF-κB plays an important role in B-cell development. The treatment of DLBCL-derived cell lines with inhibitors of the multi-subunit IκB kinase (IKK) complex, the main activator of the NF-κB pathway, demonstrated that these drugs block the proliferation of ABC-DLBCL cells before inducing cell death [65]. In this way, in vitro approaches targeting the MYD88L265-promoted myddosome assembly, which results in a constitutive NF-κB activation, suggested that disruption of this structure inhibits cell survival and promotes apoptosis in ABC DLBCL with MYD88-mutations [66]. Lenalidomide, a thalidomide-derived immunomodulatory drug, also downregulates NF-κB activity, as it targets the E3 ubiquitin ligase component cereblon (CRBN) and downregulates IRF4. The effects of lenalidomide in ABC-DLBCL are associated with increased interferon β (IFN-β) production, which is pro-apoptotic, counteracting the effect of oncogenic MYD88 mutations [61,67]. Therefore, MCD-DLCBL patients could benefit from lenalidomide therapy. Despite the increasing efforts in the discovery and generation of drugs targeting NF-κB, the clinical trials performed to date have limited applicability for DLBCL patients [68,69].

The JAK/STAT3 signaling pathway is also a key candidate for drug targeting. STAT3 and JAK1 are activated in ABC-DLBCL by autocrine production of the cytokines IL-6 and IL-10, promoting cell survival. The decrease in STAT3 activation induces apoptosis in DLBCL cell lines [70]. Additionally, JAK inhibitors decrease cell viability in ABC-DLBCL cell lines [59]. Both therapeutic strategies are promising candidates for ST2-DLBCL genetic subtype patients.

The PI3K/AKT pathway is another potential therapeutic target in B-cell lymphomas. There are several PI3K inhibitors, both pan-PI3K inhibitors and specific inhibitors of any of the PI3K isoforms. Their activity has been tested in several DLBCL-derived cell lines, and the results suggest that the simultaneous blocking of PI3Kα/δ is the most effective strategy in DLBCL treatment (47). Moreover, drug synergism studies proposed a combination of PI3Kα/δ and BCL2 blockade, using venetoclax, in BCR-dependent DLBCL cell lines [71], or even the use of a combination of PI3K and BTK inhibitors, to overcome ibrutinib resistance in ABC-DLBCL cell lines [72].

The therapeutic targeting of epigenetic regulators has also been studied in lymphoma-derived cell lines. One of the most important targets in this area is EZH2. The EZH2 inhibitor EZH2i blocks proliferation in EZH2 mutant DLBCL cell lines [73], and even in EZH2 wild-type lymphoma cells [29,31,74]. Moreover, dual targeting of EZH1/2 has been shown to be even more effective [75]. The results from these studies could form the basis for personalized medicine for EZB-DLBCL patients or GCB-DLBCL overexpressing EZH2 wild-type and /or mutants [76]. Several studies of B-cell lymphoma cell lines showed that HDAC inhibitors can suppress tumor growth via multiple mechanisms, including the induction of cell death, up-regulation of MHC [77] and/or PD-L1 [78], and activation of Treg (for a recent review, see [79]). Interestingly, some HDAC inhibitors, such as romidepsin, panobinostat, vorinostat, and belinostat, are already approved and used for hematological cancers in daily clinical practice [79].

Finally, alterations in NOTCH signaling are also involved in lymphomagenesis, and it could therefore be a promising target for DLBCL therapy. There have been few studies in this field, although it has been shown that gamma-secretase inhibitors may be of therapeutic value in DLBCL [80], especially for N1 DLCBL patients. The therapeutic strategies for targeting this pathway remain largely unexplored.

Constitutive overexpression of BCL2 and MYC usually occurs in DLBCL, making them potential therapeutic targets. MYC is epigenetically modulated by the bromodomain and extra terminal (BET) protein. In vitro experiments provide a rationale for using BET inhibitors alone or in combination with BCL2 inhibitors for DHL/THL DLBCLs [81,82].
Additionally, BCL6 is overexpressed in over half of DLBCL cases, regardless the COO. Both BCL6 peptide inhibitors and small molecule inhibitors have been shown to have potent efficacy against B-cell lymphoma cells [83,84] and BCL6-dependent DLBCL cell lines [85]. These results are suggestive of a potentially good therapeutic strategy for BN2-DLBCL patients.

Unlike cell suspensions which are obtained directly from fresh biopsies, human cell lines are a self-renewing resource containing most genetic alterations in the original tumor [86]. The extensive propagation of cell lines and potential handling-derived stresses lead to genetic inconsistencies in cancer cell lines that cause apparently standardized cells to behave differently from one another [87]. Additionally, the lack of microenvironment and other cell types in the culture, which are crucial in B-cell lymphomas, give rise to different transcriptomic and proteomic signatures in cell lines than in primary lymphomas [86].

3.3. Of Mice and Men: Understanding Lymphoma Biology

In the field of lymphoma research, the mouse has been the model organism due to its genetic and physiological similarity to humans (Table 2) [88,89]. Various spontaneous tumor models (such as the Eμ-Myc, Eμ-BRD2, or Bcl6 mouse models) have been developed to study how B-cell lymphomas arise and mature in different tumor environments [90–92]. However, genetically engineered mouse (GEM) models (Figure 2C) have enabled the recapitulation of DLBCL genomic complexity, and have been very useful for defining the genetic causes of lymphoma [93]. Indeed, these models have clarified the understanding of the role of BCR signaling, germinal center differentiation status (by the identification of factors such as BCL6, SPIB, PAX5, and EZH2, among others), B-cell development regulators (such as PI3K) in lymphomagenesis, the study of malignant transformation drivers (such as MEF2B) and tumor suppressors (such as TET2 or CREBBP), functional cooperation between B-cell pathways (such as BCR and TLR signaling), and the identification of potential targets for drug intervention [58,94–98].

The Eμ-Myc mouse model has been paradigmatic in our understanding of B-cell lymphomagenesis and the effect of novel therapies in lymphoma progression [90]. These mice carry a DNA construct of the murine c-Myc gene, in combination with an IgH enhancer, which leads to 90% of the heterogenetic offspring developing an early-onset immature form resembling BL, and a more indolent mature form resembling DLBCL [99]. This model has enabled the identification of essential factors for tumor survival (such as spleen tyrosine kinase (SYK) in NHL) and co-operative tumor suppressor genes in B-cell lymphoma. It has also led to the generation of new preclinical mouse models by the translocation of the N-myc gene in different enhancer regions combined with retroviral infection to accelerate and enhance lymphomagenesis, such as the Eμ-BRD2 DLBCL mouse model, or others that recapitulate complex lymphoma scenarios, such as aggressive B-cell lymphoma in the context of chronic lymphocytic leukemia [91,100–102].
### Table 2. Currently available DLBCL mouse models (overview). DLBCL: Diffuse large B-cell lymphoma; GC: germinal center B-cell like; ABC: activated B-cell like; (m): murine origin; (h): human origin; iv: intravenous; ip: intraperitoneal; sc: subcutaneous; PDX: patient derived xenograft; PDO: patient derived organoid.

| Strategy | Phenotype/Incidence | Prospective Uses |
|----------|---------------------|------------------|
| **Genetically engineered mice** | | |
| Eμ-Myc | DLBCL (time dependent) | | |
| Eμ-BRD2 | DLBCL | | |
| Bcl6 Knock in | GC-DLBCL | | |
| Bcl6/Myc | ABC-DLBCL | | |
| Iμ:HA.BCL6 | 36–62% lymphoma incidence | Combination with conditional Spen and Tnfaip3 knockout or oncogenic Notch2 alleles to model Cluster BN2 |
| M61.Cre, Eμ:Bcl2, Crebbp/fl/fl | GC-DLBCL | Combination of the different alleles to generate a sophisticated EZB mouse model |
| Cγ1Cre/wt, Kmt2d/fl/fl, VavP:Bcl2 | 21% incidence | Modeling of the MCD cluster by combination of both alleles and a newly generated CD79B cond.p.Y196H/wt allele, or with the already existing Prdm1fl/fl |
| Ezh2cond.p.Y641F/wt, VavP:Bcl2, Cγ1Cre/wt | DLBCL-like lymphoma | | |
| Cd19 Cre/wt, Myd88cond.p.L252P/wt, Rosa26LSL.BCL2-IRES-GFP/wt | 85% incidence | | |
| Cγ1Cre, Prdm1fl/fl, Rosa26LSL.IKK2ca | 50% incidence IRF4, post-GC DLBCL | | |
| **Syngeneic models** | | |
| Pi-BCLI (m) iv or ip in BALB/c immunocompetent mice | DLBCL | Gene editing |
| A20 (m) iv, intrasplenic, or sc injection in BALB/c immunocompetent mice | DLBCL | Generation of complex organoids prior to inoculation of the cell line |
| **Xenograft models** | | |
| SU-DHL-4 (h) iv or sc in SCID immunodeficient mice | DLBCL | Gene editing |
| Transduced HPCs in irradiated mice | GC- and ABC-DLBCL | Generation of a-la-carte HPCs reproducing the genetic signatures |
| PDX iv or sc in immunodeficient mice | 20–30% successful engraftment | Use of humanized mice to study lymphoma physiology and drug responses |
| PDO iv or sc in immunodeficient mice | 20–30% successful engraftment | Personalized medicine |

The headings of each mouse model subtype are highlighted in bold.
Targeted gene editing of mice initially generated germinal center (Bcl6 knock-in) and post-germinal center (Bcl6/Myc transgenic) DLBCL mouse models [92]. In recent years, there has been a particular focus on the generation of models which capture the genomic complexity of the molecularly-defined DLBCL subtypes described in the Advances in DLBCL genomics section, by two distinct strategies: the generation of autochthonous mice, combining the use of conditional alleles with a certain genetic background, or by transplantation of hematopoietic progenitor cells (HPCs) transduced with selected repressors or enhancers in irradiated mice.

These strategies have given rise to mouse models with different genetic backgrounds, which can be used to study the recently described BN2, EZB, and MCD DLBCL subtypes (for a review, see [116]).

DLBCL samples belonging to the BN2 subtype are characterized by the co-occurrence of BCL6 rearrangements with aberrations in NOTCH2, SPEN, BCL10, and TNFAIP3. The combination of conditional Spen and Tnfaip3 knockout or oncogenic Notch2 alleles (which are not sufficient to generate lymphomagenesis per se) with the Iṣ teenage Bcl6 knock-in DLBCL mouse model, characterized by a deregulated BCL6 expression that leads to the development of human DLBCL-like lymphomas, might fit as a robust mouse model for this subtype [92,117–119]. However, no research has been carried out using this model to date.

The hallmark features of DLBCL samples belonging to the EZB subtype are genetic alterations in BCL2 that lead to enhanced BCL2 expression, and mutations in genes encoding epigenetic modifiers such as KMT2D, CREBBP, or EZH2. The conditional deletion of Kmt2d in mice early in the B-cell development process, combined with Bcl2 overexpression using Cγ1Cre;Kmt2dfl/fl;VavP:Bin mice resulted in DLBCL lymphomagenesis [104]. The transplantation of Kmt2d-depleted HPCs into irradiated wild-type recipient mice resulted in clonal high-grade FL, not DLBCL, highlighting the functional relevance of the co-clustering of BCL2 and KMT2D aberrations in these DLBCLs [120]. Likewise, CREBBP loss also cooperates with BCL2 overexpression in DLBCL lymphomagenesis as shown in Mbi:Cre;Eṣ:Bin;Crebbpfl/fl mice and in an HPC transplantation model involving VavP:Bcl2-derived HPCs transduced with Crebbp- or Ep300-shRNA transplantation into irradiated mice [103,115]. Consistent with this, oncogenic mutations in Ezh2, combined with Bcl2 overexpression, also gave rise to early onset DLBCL lymphomas in Cγ1Cre;VavP:Bcl2;Ezh2Y641F/N and irradiated wild-type mice transplanted with Ezh2Y641F-transduced VaeP:Bcl2-derived HPCs [105,121].

Co-occurring mutations in MYD88 and CD79B, and PRMDI inactivation characterize MCD subtype DLBCLs. The B-cell-specific depletion of Prdm1 leads to blocked plasma cell differentiation in mice (such as Cdll19Cre;Prdm1fl/fl and Cγ1Cre;Prdm1fl/fl mice models). This has been combined with a constitutive active IKK2-bearing allele to generate ABC-DLBCL-bearing mice (Cγ1Cre;Prdm1fl/fl;Rosa26LSL.IKK2ca). However, IKK2 mutations are not recurrent in human DLBCL, making this mouse model a controversial one. Instead, the Cdl19Cre;Myd88γL252P/wt;Rosa26SL.BCL2-RES-GFP mouse model contains the recurrent Myd88γL252P mutation and BCL2 amplification in B-cells [106]. These mice develop lymphomas with late or post-GC origin ABC-DLBCL phenotype, with an actionable dependence on BCL2 [122]. This model can be further combined with the aforementioned mouse models carrying the Myd88γL252P mutation for a better understanding of the lymphoma physiology of this subtype, as these mutations co-cluster in patients.

In short, this field is still laying the foundation to generate the perfect mouse model which reproduces the desired genomic complexity that will lead to genotype-tailored molecular intervention strategies for DLBCL patients. The application of the CRISPR-Cas9 system in GEM is a promising field of biomedical research as it can be performed directly, in a single step, in mouse zygotes by microinjection or electroporation, and
allows for the simultaneous manipulation of multiple genes to mimic human disease complexity [123,124].

As useful as they are as a tool to understand the importance of certain genes or gene combinations in lymphomagenesis, GEMs lack the genomic complexity of the tumor, as they only reproduce selected alterations in a complex pathology.

Disseminated or widely distributed diseases (such as DLBCL) are efficiently reproduced by the intraperitoneal or intravascular injection of lymphoma cells via the tail vein in mice [109,125]. However, transplantable models of lymphoma involving the implantation of histocompatible allografts (syngeneic) or foreign xenografts into mice, maintain better tumor complexity, especially that due to the microenvironment.

DLBCL syngeneic mouse models are generated by the injection of A20 or Pi-BCL1 murine lymphoma cell lines into immunocompetent hosts. These models facilitate the study of lymphoma biology, tumor microenvironment, and the effect of drugs in the presence of an intact immune system [126–128], and can be successfully edited using the CRISPR/Cas9 system [48]. Their main limitation is that murine-based therapies in a murine system do not guarantee similar effects in humans [129,130].

Xenograft mouse models entail the transplantation of human lymphoma cells (either patient-derived, PDX, or cell lines, CDX) into immunodeficient mice (Figure 2D), thereby favoring tumor engraftment [93]. CDX models, e.g., those generated by SU-DHL-4 injection, are useful for initial drug screenings, but cell lines contain native mutations that may not be observed in the comparative human lymphoma [113,126,131–133]. PDXs, on the other hand, retain primary lymphoma characteristics, including TME, genetic signature and refractoriness to treatment. This allows for the rigorous testing of drug treatments and therapeutic regimens for lymphomas and is useful for personalized drug therapy [93,131,134,135]. Unfortunately, engraftment rates tend to be low, and PDXs are commonly transplanted into immune-compromised mice to avoid rejection, limiting the opportunities to study immune interactions [93,136]. This limitation can be overcome by serial engraftment, which involves passing a successfully engrafted lymphoma into other mice. However, it leads to the gradual loss of primary tumor characteristics, which is an undesirable side effect [136].

The use of immunodeficient mice populated with a human immune system (humanized mice) to study immune interactions is becoming increasingly common in the field [137,138]. These mice have the potential to bring novel cancer therapies to light that rely on a functional immune response and can be generated from a healthy donor or the patient’s own immune cells. In the B-cell lymphomas field, humanized mice are used to investigate the transition of EBV to B-cell lymphomas [139,140].

3.4. Back to the Bench: À La Carte-Engineered Spheroids

As previously mentioned, the interaction of malignant B-cells with stromal fibroblasts, endothelial cells, and other immune cells is key to the survival and progression of DLBCL [141–143]. 2D cultures lack the complexity, intercellular interactions, hypoxic conditions, and metabolic alterations found in the primary tumor [144,145]. This has led to 3D models being increasingly used in recent years [146]. These provide promising means of overcoming this limitation by recapitulating the organ structure, microenvironment, and physiological function, reliably mimicking disease states [147].

In vitro 3D models can be generated from cell lines or directly from the primary tumor (Figure 2C). However, unlike solid tumors, which can spontaneously self-organize into tissue-like structures (organoids), lymphoma organoids (also referred to as spheroids) are artificially engaged in 3D structures and enriched in the cell types present in the primary tumor [148,149].

Even though the standardization of 3D DLBCL spheroids has been challenging, the availability of different matrices reproducing specific components of the original extracellular matrix (ECM), such as polyethylene glycol-maleimide, methylcellulose or alginate, and puramatrix, has made it possible to generate DLBCL spheroids in the presence or absence of
stroma cells. These maintain the cell shape, polarization, and spatial constraints seen in the physiological environment [150–152]. In addition, the biological responses and immune interactions between tumor and immune cells in the spheroids replicate those seen in mouse models [95,135]. However, the need to generate these spheroids afresh and the wide variety of matrices required to grow them have also complicated the use of standardized spheroids and limited the generation of highly characterized DLBCL spheroid biobanks.

Patient-derived lymphoma organoids (PDOs) reproduce the actual interactions within a patient's own immune system to eradicate tumor cells, and recapitulate the transcriptional, mutational profile, and therapy response of the primary tumor (Figure 2B,D) [153,154]. They can be directly generated from a biopsy, preserving endogenous immune cells and other cell types (holistic approach), or can be established separately from immune cells before co-culture, which facilitates the study of specific cell–cell interactions (a simplistic approach) [155]. PDOs are a promising tool for developing and testing personalized medicine approaches [156]. However, before they can be applied as part of the daily clinical routine, organoid-based bioassays need to be standardized and improved to clinical grade.

A major limitation of organoids involving different cell types is that the co-culture conditions must be optimized to achieve an equilibrium that suits all cell types involved. Additionally, patient-derived 3D models are often created from small biopsies, in part due to the increasing use of large needle gauge punches, which may underrepresent the complexity of the whole tumor, lack immune selection, and be difficult to manipulate in vitro. Access to larger biopsies could facilitate optimizing these systems and broaden the scope of these models beyond drug screenings.

Despite all these limitations, cell-line-derived DLBCL spheroids have already been used to evaluate germinal center reactions, the tumor microenvironment and therapeutic potential and resistances [95,135,157]. Spheroid systems have been used to study the signaling and epigenetic events essential for the germinal center reaction, such as the EZH2 regulation of GC B cell proliferation through the repression of CDKN1A, which cannot be examined in mouse models because mice lacking Ezh2 do not form germinal centers [156]. Cell-line-derived and patient-derived DLBCL organoids have also been used to test combination therapies in genetically defined backgrounds and to design anti-lymphoma regimens for ABC-DLBCL [159,160].

More complex systems, such as organ-on-chip models and microfluidics-based platforms, recapitulate blood-flow conditions and accurately reproduce the cell interactions that occur in the DLBCL tumor microenvironment (Figure 2B) [151,161]. Indeed, the combination of on-chip platforms with 3D matrices to mimic ECM composition and architecture can be used to incorporate molecular and cellular gradients such as those found in patients and the study of drug kinetics.

Overall, 3D models are very likely to facilitate faster and less expensive transferable drug development [162]. They are emerging as a better model than conventional established 2D cell lines for drug screening [163], because they more closely recapitulate the TME of primary tumors. Although animal models remain essential, 3D models could eventually reduce the use of animals for drug testing and, therefore, lower costs, shorten the time taken to obtain results, and enable the avoidance of ethical issues.

As useful as 3D culture models already are, the future of organoid systems points to the generation of 4D systems that dynamically respond to microenvironmental changes in the biochemical, physicochemical, and biophysical properties of the microenvironment, to offer more accurate physiological models to recreate lymphoid-like structures.

4. Conclusions

Massive sequencing has been used to identify genetic signatures in lymphomas that help predict which patients could benefit from the standard treatment and their outcome, and to enable the proposal of alternative therapeutic approaches.

Functional assays should provide the information needed to fill the knowledge gap between genomic information and treatment. Established experimental models, such as
tumor cell lines and mice, do not completely capture the complex genetic and epigenetic landscape that each patient presents, so the translation of findings from these models to the clinical setting is not yet efficient. However, the emergence of 3D models such as spheroids/organoids, which can be generated from several cell types and reproduce the interactions of the patients’ immune system with their tumor, are promising tools that could be used in personalized medicine approaches in the near future (Figure 3).

**Figure 3.** The near future for B-cell lymphoma patients: genetic signatures lead to personalized treatments. Recent studies have identified genetic signatures in diffuse large B-cell lymphoma (DLBCL) patients that can be used to predict outcome and therapy response. In the near future, a combination of newly adapted routines in daily clinical practice (left) and basic research (right) are very likely to lead to personalized treatments for B-cell lymphoma patients, based on the genetic profile of their biopsies. To this end, gene edition of DLBCL cell lines in the laboratory will enable the replication of the DLBCL genetic subtypes (GS) identified in patients (BN2, N1, EZB, MCD, and ST2). 3D organoid-based drug screenings will establish the sensitivities of the different genetic variants to single drugs or drug combinations, at the dose and posology levels, while maintaining the lymphoma microenvironment and intercellular interactions. Once a GS has been matched to a certain treatment regimen, drug sensitivity should be validated in organoids derived from fresh patient biopsies (patient derived organoids, PDOs). Inclusion of biopsy sequencing using targeted panels of selected genes as part of the daily clinical routine will eventually allow personalized treatments to be directly assigned based on the GS of patient biopsies, optimized treatment-response rates, and improved overall survival. FFPE: formalin-fixed, paraffin-embedded.
We believe that combining gene editing and 3D cultures will soon allow for the replication of the genetic signatures identified in lymphoma patients, in cell lines, or primary cells in vitro, reproducing the tumor microenvironment and immune interactions. This will very likely prompt a shift in our understanding of the relevance of these clusters of mutations in therapy responses and lymphoma progression, and, more importantly, may inform the design of patient-specific therapies.

Author Contributions: N.Y.-C. and M.S.-B. contributed to conception, design, and revision of the study and wrote the first draft of the manuscript; N.Y.-C., L.P. and I.F.-M. wrote sections of the manuscript; N.Y.-C. prepared the figures. All authors contributed to manuscript revision. All authors have read and agreed to the published version of the manuscript.

Funding: The lab work is supported by grants from the Spanish Ministry of Economy and Competence (MINECO), ISCIII-MINECO AES-FEDER (Plan Estatal de I+D+I 2013–2016 and 2017–2020) (DT17/00039, PI17/00272, CIBERONC CB16/12/00291), Dirección General de Universidades e Investigación Consejería de Educación e Investigación de la Comunidad de Madrid (B2017/BMD-3778) and GILEAD (GLD18/00019). N.Y.C. is supported by the Asociación Española Contra el Cáncer AECC Scientific Foundation, L.P. is supported by ISCIII-MINECO AES-FEDER 2017–2020 (IF118/0004) and IFM is supported by B2017/BMD-3778.

Ethics Approval and Consent to Participate: Not applicable.

Consent for Publication: All authors consent to publication.

Availability of Data and Materials: Not applicable.

Acknowledgments: We would like to thank Ignacio Perez de Castro, Sagrario Gómez de Benito, Marta Navarro, and Beatriz Horcajo for their critical reading of the manuscript.

Conflicts of Interest: The authors declare that they have no competing interests.

References

1. Bakhshi, T.J.; Georgel, P.T. Genetic and Epigenetic Determinants of Diffuse Large B-Cell Lymphoma. Blood Cancer J. 2020, 10, 1–23. [CrossRef] [PubMed]
2. Sant, M.; Allemani, C.; Tereanu, C.; De Angelis, R.; Capocaccia, R.; Visser, O.; Marcos-Gragera, R.; Maynadié, M.; Simonetti, A.; Lutz, J.-M.; et al. Incidence of Hematologic Malignancies in Europe by Morphologic Subtype: Results of the HAEMACARE Project. Blood 2010, 116, 3724–3734. [CrossRef] [PubMed]
3. Howlader, N.; Noone, A.M.; Krapcho, M.; Miller, D.; Brest, A.; Y, M.; Ruhl, J.; Tatalovich, Z.; Mariotto, A.; Lewis, D.R.; et al. Diffuse Large B-Cell Lymphoma—Cancer Stat Facts. 2019. Available online: https://seer.cancer.gov/statfacts/html/dlbcl.html (accessed on 18 May 2021).
4. Sehn, L.H.; Salles, G. Diffuse Large B-Cell Lymphoma. N. Engl. J. Med. 2021. [CrossRef]
5. Alizadeh, A.A.; Eisen, M.B.; Davis, R.E.; Ma, C.; Lossos, I.S.; Rosenwald, A.; Boldrick, J.C.; Sabet, H.; Tran, T.; Yu, X.; et al. Distinct Types of Diffuse Large B-Cell Lymphoma Identified by Gene Expression Profiling. Nature 2000, 403, 503–511. [CrossRef] [PubMed]
6. Rosenwald, A.; Wright, G.; Chan, W.C.; Connors, J.M.; Campo, E.; Fisher, R.I.; Gascoyne, R.D.; Muller-Hermelink, H.K.; Smeland, E.B.; Giltman, J.M.; et al. The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma. N. Engl. J. Med. 2002, 346, 1937–1947. [CrossRef]
7. Jaffe, E.S.; Barr, P.M.; Smith, S.M. Understanding the New WHO Classification of Lymphoid Malignancies: Why It’s Important and How It Will Affect Practice. Am. Soc. Clin. Oncol. Educ. Book 2017, 37, 535–546. [CrossRef]
8. Campo, E.; Harris, N.L.; Jaffe, E.S.; Pileri, S.A.; Stein, H.; Thiele, J.; Vardiman, J.W. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues; International Agency for Research on Cancer: Lyon, France, 2008; ISBN 978-92-832-4494-3.
9. Swerdlow, S.H.; Campo, E.; Harris, N.L.; Jaffe, E.S.; Pileri, S.A.; Stein, H.; Siebert, R.; Advani, R.; Ghielmini, M.; Salles, G.A.; Zelenetz, A.D.; et al. The 2016 Revision of the World Health Organization Classification of Lymphoid Neoplasms. Blood 2016, 127, 2375–2390. [CrossRef]
10. Basso, K.; Dalla-Favera, R. Germinal Centres and B Cell Lymphomagenesis. Nat. Rev. Immunol. 2015, 15, 172–184. [CrossRef]
11. Pasqualucci, L.; Trifonov, V.; Fabbris, G.; Ma, J.; Rossi, D.; Chiarenza, A.; Wells, V.A.; Grunn, A.; Messina, M.; Elliot, O.; et al. Analysis of the Coding Genome of Diffuse Large B-Cell Lymphoma. Nat. Genet. 2011, 43, 830. [CrossRef]
12. Dubois, S.; Viailly, P.-J.; Mareschal, S.; Boehs, E.; Bertrand, P.; Ruminy, P.; Maingonnat, C.; Jais, J.-P.; Peyrouze, P.; Figeac, M.; et al. Next-Generation Sequencing in Diffuse Large B-Cell Lymphoma Highlights Molecular Divergence and Therapeutic Opportunities: A LYSA Study. Clin. Cancer Res. 2016, 22, 2919–2928. [CrossRef]
36. Young, R.M.; Phelan, J.D.; Wilson, W.H.; Staudt, L.M. Pathogenic B-Cell Receptor Sensing in Lymphoid Malignancies: New Insights to Improve Treatment. *Immunol. Rev.* 2019, 291, 190–213. [CrossRef]

37. Young, R.M.; Phelan, J.D.; Shaffer, A.L.; Wright, G.W.; Huang, D.W.; Schmitz, R.; Johnson, C.; Oellerich, T.; Wilson, W.; Staudt, L.M. Taming the Heterogeneity of Aggressive Lymphomas for Precision Therapy. *Annu. Rev. Cancer Biol.* 2019, 3, 429–455. [CrossRef]

38. Ciavarella, S.; Vegliante, M.C.; Fabbri, M.; De Summa, S.; Melle, F.; Motta, G.; De Iuliiis, V.; Opinto, G.; Enjuanes, A.; Rega, S.; et al. Dissection of DLBCL Microenvironment Provides a Gene Expression-Based Predictor of Survival Applicable to Formalin-Fixed Paraffin-Embedded Tissue. *Ann. Oncol.* 2018, 29, 2363–2370. [CrossRef] [PubMed]

39. Hanahan, D.; Weinberg, R.A. Hallmarks of Cancer: The next generation. *Cell* 2011, 144, 646–674. [CrossRef] [PubMed]

40. Scott, D.W.; Gascoyne, R.D. The Tumour Microenvironment in B Cell Lymphomas. *Nat. Rev. Cancer* 2014, 14, 517–534. [CrossRef]

41. Kotlov, N.; Bagaev, A.; Revuelta, M.V.; Phillip, J.M.; Cacciapuoti, M.T.; Antysyeva, Z.; Svekolkin, V.; Tikhonova, E.; Miheecheva, N.; Kuzkina, N.; et al. Clinical and Biological Subtypes of B-Cell Lymphoma Revealed by Microenvironmental Signatures. *Cancer Discov.* 2021, 11, 356–369. [CrossRef]

42. Clozel, T.; Yang, S.; Elstrom, R.L.; Tam, W.; Martin, P.; Kormaksson, M.; Banerjee, S.; Vasanathakumar, A.; Culjkovic, B.; Scott, D.W.; et al. Mechanism-Based Epigenetic Chemosensitization Therapy of Diffuse Large B-Cell Lymphoma. *Cancer Discov.* 2013, 3, 1002–1019. [CrossRef]

43. Mulder, T.A.; Wahlin, B.E.; Österborg, A.; Palma, M. Targeting the Immune Microenvironment in Lymphomas of B-Cell Origin: From Biology to Clinical Application. *Cancers* 2019, 11, 915. [CrossRef]

44. Gaudelli, N.M.; Komor, A.C.; Rees, H.A.; Packer, M.S.; Badran, A.H.; Bryson, D.I.; Liu, D.R. Programmable Base Editing of A•T to G•C in Genomic DNA without DNA Cleavage. *Nature* 2017, 551, 464–471. [CrossRef]

45. Cox, D.B.T.; Platt, R.J.; Zhang, F. Therapeutic Genome Editing: Prospects and Challenges. *Nat. Med.* 2015, 21, 121–131. [CrossRef]

46. Caeser, R.; Di Re, M.; Krupka, J.A.; Gao, J.; Lara-Chica, M.; Dias, J.M.L.; Cooke, S.L.; Fenner, R.; Usheva, Z.; Runge, H.F.P.; et al. Genetic Modification of Primary Human B Cells to Model High-Grade Lymphoma. *Nat. Commun.* 2019, 10, 4543. [CrossRef]

47. Bai, B.; Myklebust, J.H.; Wälchli, S. Gene Editing in B-Lymphoma Cell Lines Using CRISPR/Cas9 Technology. *Methods Mol. Biol.* 2020, 2115, 445–454. [CrossRef]

48. Felce, S.L.; Anderson, A.P.; Maguire, S.; Gascoyne, D.M.; Armstrong, R.N.; Wong, K.K.; Li, D.; Banham, A.H. CRISPR/Cas9-Mediated Foxp1 Silencing Restores Immune Surveillance in an Immunocompetent A20 Lymphoma Model. *Front. Oncol.* 2020, 10, 448. [CrossRef]

49. Greiner, V.; Puerto, R.B.; Liu, S.; Herbel, C.; Carmona, E.M.; Goldberg, M.S. CRISPR-Mediated Editing of the B Cell Receptor in Primary Human B Cells. *iScience* 2019, 12, 369–378. [CrossRef]

50. Schlageter, S.; Salomon, C.; Olt, S.; Albrecht, C.; Ebert, A.; Bergner, O.; Wachter, J.; Trapani, F.; Gerlach, D.; Voss, T.; et al. Inducible Knock-out of BCL6 in Lymphoma Cells Results in Tumor Stasis. *Oncotarget* 2020, 11, 875–890. [CrossRef]

51. Nie, M.; Du, L.; Zhang, B.; Ren, W.; Jorg, J.; Ye, X.; Fuenzalida, J.A.; Shi, X.; Liu, D.; Wu, K.; et al. Essentiality of CREBBP in Activated B Cell-like Diffuse Large B Cell Lymphoma. *Exp. Hematol.* 2020, 646–674. [CrossRef] [PubMed]

52. Eyquem, J.; Mansilla-Soto, J.; Giavridis, T.; van der Stegen, S.J.C.; Hamieh, M.; Cunanan, K.M.; Odak, A.; Gönen, M.; Sadelain, M.; et al. Systematic Identification of Genomic Markers of Drug Sensitivity in Cancer Cells. *Nature* 2011, 569, 517–534. [CrossRef] [PubMed]

53. Garnett, M.J.; Edelman, E.J.; Heidorn, S.J.; Greenman, C.D.; Dastur, A.; Lau, K.W.; Thompson, I.R.; Luo, X.; Soares, J.; et al. Systematic Identification of Genomic Markers of Drug Sensitivity in Cancer Cells. *Nature* 2012, 483, 507–570. [CrossRef] [PubMed]

54. Greiner, V.; Puerto, R.B.; Liu, S.; Herbel, C.; Carmona, E.M.; Goldberg, M.S. CRISPR-Mediated Editing of the B Cell Receptor in Primary Human B Cells. *iScience* 2019, 12, 369–378. [CrossRef]

55. Havierty, P.M.; Lin, E.; Tan, J.; Yu, Y.; Lam, B.; Lianoglou, S.; Neve, R.M.; Martin, S.; Settleman, J.; Yang, S.; et al. Reproducible Pharmacogenomic Characterization of Cancer Cell Line Panels. *Nature* 2016, 533, 333–337. [CrossRef] [PubMed]

56. Ghandi, M.; Huang, F.W.; Jan-R, J.; Kryukov, G.V.; Lo, C.C.; McDonald, E.R.; Barretina, J.; Gelfand, E.T.; Bielski, C.M.; Li, H.; et al. Next-Generation Characterization of the Cancer Cell Line Encyclopedia. *Nature* 2019, 569, 503–508. [CrossRef]

57. Quentmeier, H.; Pommerenke, C.; Dirks, W.G.; Eberth, S.; Koeppel, M.; MacLeod, R.A.F.; Nagel, S.; Steube, K.; Uphoff, C.C.; Drexler, H.G. The LL-100 Panel: 100 Cell Lines for Blood Cancer Studies. *Nature* 2018, 569, 387–391. [CrossRef] [PubMed]

58. Quentmeier, H.; Pommerenke, C.; Dirks, W.G.; Eberth, S.; Koeppel, M.; MacLeod, R.A.F.; Nagel, S.; Steube, K.; Uphoff, C.C.; Drexler, H.G. The LL-100 Panel: 100 Cell Lines for Blood Cancer Studies. *Nature* 2018, 569, 387–391. [CrossRef] [PubMed]

59. Quentmeier, H.; Pommerenke, C.; Dirks, W.G.; Eberth, S.; Koeppel, M.; MacLeod, R.A.F.; Nagel, S.; Steube, K.; Uphoff, C.C.; Drexler, H.G. The LL-100 Panel: 100 Cell Lines for Blood Cancer Studies. *Nature* 2018, 569, 387–391. [CrossRef] [PubMed]

60. Solomon, L.A.; Batista, C.R.; DeKoter, R.P. Lenalidomide Modulates Gene Expression in Human ABC-DLBCL Cells by Regulating BIRC5 Expression. *BioRxiv* 569, 746594. [CrossRef]

61. Yang, Y.; Shaffer, A.L.; Emre, N.C.T.; Ceribelli, M.; Zhang, M.; Wright, G.; Yao, W.; Powell, J.; Platig, J.; Kolesnikova, E.; et al. Exploiting Synthetic Lethality for the Therapy of ABC Diffuse Large B Cell Lymphoma. *Cancer Cell* 2012, 21, 723–737. [CrossRef]

62. Davis, R.E.; Brown, K.D.; Siebenlist, U.; Staudt, L.M. Constitutive Nuclear Factor KappaB Activity Is Required for Survival of Activated B Cell-like Diffuse Large B Cell Lymphoma Cells. *J. Exp. Med.* 2001, 194, 1861–1874. [CrossRef]
63. Wilson, W.H.; Young, R.M.; Schmitz, R.; Yang, Y.; Pittaluga, S.; Wright, G.; Lih, C.-J.; Williams, P.M.; Shaffer, A.L.; Gerecitano, J.; et al. Targeting B Cell Receptor Signaling with Ibrutinib in Diffuse Large B Cell Lymphoma. *Nat. Med.* 2015, 21, 922–926. [CrossRef] [PubMed]

64. Wen, T.; Wang, J.; Shi, Y.; Qian, H.; Liu, P. Inhibitors Targeting Bruton’s Tyrosine Kinase in Cancers: Drug Development Advances. *Leukemia* 2021, 35, 312–332. [CrossRef]

65. Lam, L.T.; Davis, R.E.; Pierce, J.; Hepperle, M.; Xu, Y.; Hottelet, M.; Nong, Y.; Wen, D.; Adams, J.; Dang, L.; et al. Small Molecule Inhibitors of IkappaB Kinase Are Selectively Toxic for Subgroups of Diffuse Large B-Cell Lymphoma Defined by Gene Expression Profiling. *Clin. Cancer Res.* 2005, 11, 28–40. [PubMed]

66. Wang, X.; Tan, Y.; Huang, Z.; Huang, N.; Gao, M.; Zhou, F.; Hu, J.; Feng, W. Disrupting Mydosome Assembly in Diffuse Large B-cell Lymphoma Cells Using the MYD88 Dimerization Inhibitor ST2825. *Oncol. Rep.* 2019, 42, 1755–1766. [PubMed]

67. Zhang, L.-H.; Kosek, J.; Wang, M.; Heise, C.; Schafer, P.H.; Chopra, R. Lenalidomide Efficacy in Activated B-Cell-like Subtype Diffuse Large B-Cell Lymphoma Is Dependent upon IRF4 and Cereblon Expression. *Br. J. Haematol.* 2013, 160, 487–502. [CrossRef] [PubMed]

68. Ramadass, V.; Vaiapuri, T.; Tergaonkar, V. Small Molecule NF-KB Pathway Inhibitors in Clinic. *Int. J. Mol. Sci.* 2020, 21, 5164. [CrossRef]

69. Chiappella, A.; Santambrogio, E.; Castellino, A.; Nicolosi, M.; Vitolo, U. Integrating Novel Drugs to Chemomimethotherapy in Diffuse Large B-Cell Lymphoma. *Expert Rev. Hematol.* 2017, 10, 697–705. [CrossRef] [PubMed]

70. Sun, X.; Li, B.; Xie, B.; Xu, Z.; Chang, G.; Tao, Y.; Zhang, Y.; Chang, S.; Wang, Y.; Yu, D.; et al. DCZ3301, a Novel Cytotoxic Agent, Inhibits Proliferation in Diffuse Large B-Cell Lymphoma via the STAT3 Pathway. *Cell Death Dis.* 2017, 8, e3111. [CrossRef]

71. Bojarczuk, K.; Wienand, K.; Ryan, J.A.; Chen, L.; Villalobos-Ortiz, M.; Mandato, E.; Stachura, J.; Letai, A.; Lawton, L.N.; Chapuy, B.; et al. Targeted Inhibition of PI3Kα/δ Is Synergistic with BCL-2 Blockade in Genetically Defined Subtypes of DLBCL. *Blood* 2019, 133, 78–80. [CrossRef]

72. Yahiaoui, A.; Meadows, S.A.; Sorensen, R.A.; Cui, Z.-H.; Keegan, K.S.; Brockett, R.; Chen, G.; Quev, C.; Li, L.; Tannheimer, S.L. PI3Kδ Inhibitor Idelalisib in Combination with BTK Inhibitor ONO-GS-4059 in Diffuse Large B Cell Lymphoma with Acquired Resistance to PI3Kδ and BTK Inhibitors. *PloS ONE* 2017, 12, e0171221. [CrossRef]

73. McCabe, M.T.; Ott, H.M.; Ganji, G.; Korenchuk, S.; Thompson, C.; Van Aller, G.S.; Liu, Y.; Graves, A.P.; Iii, A.D.P.; Diaz, E.; et al. EZH2 Inhibition as a Therapeutic Strategy for Lymphoma with EZH2-Activating Mutations. *Nature* 2012, 492, 108–112. [CrossRef]

74. Knutson, S.K.; Kawano, S.; Minoshima, Y.; Warbolic, N.M.; Huang, K.-C.; Xiao, Y.; Kadowaki, T.; Uesugi, M.; Kuznetsov, G.; Kumar, N.; et al. Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in EZH2-Mutant Non-Hodgkin Lymphoma. *Mol. Cancer Ther.* 2014, 13, 842–854. [PubMed]

75. Yamagishi, M.; Hori, M.; Fujikawa, D.; Ohsugi, T.; Honma, D.; Adachi, N.; Katano, H.; Hishima, T.; Kobayashi, S.; Nakano, K.; et al. Targeting Excessive EZH1 and EZH2 Activities for Abnormal Histone Methylation and Transcription Network in Malignant Lymphomas. *Cell Rep.* 2019, 29, 2321–2337.e7. [CrossRef]

76. Camica, R.; Winkler, H.C.; Hassa, P.O. Novel Drug Targets for Personalized Precision Medicine in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Comprehensive Review. *Mol. Cancer* 2015, 14, 207. [CrossRef] [PubMed]

77. Cycon, K.A.; Mulvaney, K.; Rimsza, L.M.; Persky, D.; Murphy, S.P. Histone Deacetylase Inhibitors Activate CIITA and MHC Class II Antigen Expression in Diffuse Large B-Cell Lymphoma. *Immunology* 2013, 140, 259–272. [CrossRef] [PubMed]

78. Deng, S.; Hu, Q.; Zhang, H.; Yang, F.; Peng, C.; Huang, C. HADAC3 Inhibition Upregulates PD-L1 Expression in B-Cell Lymphomas and Augments the Efficacy of Anti-PD-L1 Therapy. *Mol. Cancer Ther.* 2019, 18, 900–908. [CrossRef]

79. Wang, X.; Waschke, B.C.; Woolaler, R.A.; Chen, S.M.Y.; Chen, Z.; Wang, J.H. HDAC Inhibitors Overcome Immunotherapy Resistance in B-Cell Lymphoma. *Protein Cell* 2020, 11, 472–482. [CrossRef] [PubMed]

80. Tohda, S.; Sato, T.; Kogoshi, H.; Fu, L.; Sakano, S.; Nara, N. Establishment of a Novel B-Cell Lymphoma Cell Line with Suppressed Expression of CD19. *Leuk. Res.* 2006, 30, 1385–1390. [CrossRef]

81. Takimoto-Shimomura, T.; Tsukamoto, T.; Maegawa, S.; Fujibayashi, Y.; Matsumura-Kimoto, Y.; Mizuno, Y.; Chinen, Y.; Shimura, Y.; Mizutani, S.; Horiike, S.; et al. Dual Targeting of Bromodomain-Containing 4 by AZD5153 and BCL2 by AZD4320 against B-Cell Lymphomas Concomitantly Overexpressing c-MYC and BCL2. *Investig. New Drugs* 2019, 37, 210–222. [CrossRef]

82. Li, W.; Gupta, S.K.; Han, W.; Kundson, R.A.; Nelson, S.; Knutson, D.; Greipp, P.T.; Elsawa, S.F.; Sotomayor, E.M.; Gupta, M. Targeting MYC Activity in Double-Hit Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements with Epigenetic Bromodomain Inhibitors. *J. Hematol. Oncol.* 2019, 12, 73. [CrossRef]

83. Cerchietti, L.C.; Yang, S.N.; Shakhnovich, R.; Hatzis, K.; Polo, J.M.; Chadburn, A.; Dowdy, S.F.; Melnick, A. A Peptomimetic Inhibitor of BCL6 with Potent Antilymphoma Effects in Vitro and in Vivo. *Blood* 2009, 113, 3397–3405. [CrossRef]

84. Polo, J.M.; Dell’Oso, T.; Ranuncolo, S.M.; Cerchietti, L.; Beck, D.; Da Silva, G.F.; Prive, G.G.; Licht, J.D.; Melnick, A. Specific Peptide Interference Reveals BCL6 Transcriptional and Oncogenic Mechanisms in B-Cell Lymphomas. *Nat. Cell Biol.* 2004, 10, 1329–1335. [CrossRef] [PubMed]

85. Cerchietti, L.C.; Ghetu, A.F.; Zhu, X.; Da Silva, G.F.; Zhong, S.; Matthews, M.; Bunting, K.L.; Polo, J.M.; Farès, C.; Arrowsmith, C.H.; et al. A Small-Molecule Inhibitor of BCL6 Kills DLBCL Cells In Vitro and In Vivo. *Cancer Cell* 2010, 17, 400–411. [CrossRef]

86. Sandberg, R.; Ernberg, I. Assessment of Tumor Characteristic Gene Expression in Cell Lines Using a Tissue Similarity Index (TSI). *Proc. Natl. Acad. Sci. USA* 2005, 102, 2052–2057. [CrossRef] [PubMed]

87. Mullard, A. Can You Trust Your Cancer Cell Lines? *Nat. Rev. Drug Discov.* 2018, 17, 613. [CrossRef]
88. Kohnken, R.; Porcu, P.; Mishra, A. Overview of the Use of Murine Models in Leukemia and Lymphoma Research. Front. Oncol. 2017, 7, 22. [CrossRef]
89. Perlman, R.L. Mouse Models of Human Disease: An Evolutionary Perspective. Evol. Med. Public Health 2016, 2016, 170–176. [CrossRef]
90. Harris, A.W.; Pinkert, C.A.; Crawford, M.; Langdon, W.Y.; Brinster, R.L.; Adams, J.M. The E Mu-Myc Transgenic Mouse. A Model for High-Incidence Spontaneous Lymphoma and Leukemia of Early B Cells. J. Exp. Med. 1988, 167, 353–371. [CrossRef] [PubMed]
91. Greenwald, R.J.; Tumang, J.R.; Sinha, A.; Currier, N.; Cardiff, R.D.; Rothstein, T.L.; Faller, D.V.; Denis, G.V. E Mu-BRD2 Transgenic Mice Develop B-Cell Lymphoma and Leukemia. Blood 2004, 103, 1475–1484. [CrossRef] [PubMed]
92. Cattoretti, G.; Pasqualucci, L.; Ballon, G.; Tam, W.; Nandula, S.V.; Shen, Q.; Mo, T.; Murty, V.V.; Dalla-Favera, R. Deregulated BCL6 Expression Recapitulates the Pathogenesis of Human Diffuse Large B Cell Lymphomas in Mice. Cancer Cell 2005, 7, 445–455. [CrossRef]
93. Cho, S.-Y.; Kang, W.; Han, J.Y.; Min, S.; Kang, J.; Lee, A.; Kwon, J.Y.; Lee, C.; Park, H. An Integrative Approach to Precision Cancer Medicine Using Patient-Derived Xenografts. Mol. Cells 2016, 39, 77–86. [CrossRef] [PubMed]
94. Abdelrasoul, H.; Werner, M.; Setz, C.S.; Okkenhaug, K.; Jumaa, H. PI3K Induces B-Cell Development and Regulates B Cell Identity. Sci. Rep. 2018, 8, 1327. [CrossRef]
95. Béguelin, W.; Teater, M.; Meydan, C.; Hoehn, K.B.; Phillip, J.M.; Soshnev, A.A.; Venturutti, L.; Rivas, M.A.; Calvo-Fernández, M.T.; Gutierrez, J.; et al. Mutant EZH2 Induces a Pre-Malignant Lymphoma Niche by Reprogramming the Immune Response. Cancer Cell 2020, 37, 655–673.e11. [CrossRef]
96. Brescia, P.; Schneider, C.; Holmes, A.B.; Shen, Q.; Hussein, S.; Pasqualucci, L.; Basso, K.; Dalla-Favera, R. MEF2B Instructs Germinal Center Development and Acts as an Oncogene in B-Cell Lymphomagenesis. Cancer Cell 2018, 34, 453–465.e9. [CrossRef] [PubMed]
97. Dominguez, P.M.; Ghamlouch, H.; Rosikiewicz, W.; Kumar, P.; Béguelin, W.; Fontán, L.; Rivas, M.A.; Pawlikowska, P.; Armand, M.; Mouly, E.; et al. TET2 Deficiency Causes Germinal Center Hyperplasia, Impairs Plasma Cell Differentiation, and Promotes B-Cell Lymphomagenesis. Cancer Discov. 2018, 8, 1632–1653. [CrossRef]
98. Zhang, J.; Vlasveskova, S.; Wells, V.A.; Nataraj, S.; Holmes, A.B.; Duval, R.; Meyer, S.N.; Mo, T.; Basso, K.; Brindle, P.K.; et al. The CREBBP Acetyltransferase is a Haploinsufficient Tumor Suppressor in B-Cell Lymphoma. Cancer Discov. 2017, 7, 322–337. [CrossRef]
99. Mori, S.; Rempel, R.E.; Chang, J.T.; Yao, G.; Lagoo, A.S.; Potti, A.; Bild, A.; Nevins, J.R. Utilization of Pathway Signatures to Reveal Distinct Types of B Lymphoma in the Emicro-Myc Model and Human Diffuse Large B-Cell Lymphoma. Cancer Res. 2008, 68, 8525–8534. [CrossRef] [PubMed]
100. Lefebure, M.; Tothill, R.W.; Kruse, E.; Hawkins, E.D.; Shortt, J.; Matthews, G.M.; Gregory, G.P.; Martin, B.P.; Kelly, M.J.; Todorovski, M.; Mouly, E.; et al. Genomic Characterisation of Eµ-Myc Mouse Lymphomas Identifies Bcor as a Myc Co-Operative Tumour-Suppressor Gene. Nat. Commun. 2017, 8, 14581. [CrossRef]
101. Lucas, F.; Rogers, K.A.; Harrington, B.K.; Pan, A.; Yu, L.; Breitbach, J.; Bundschuh, R.; Goettl, V.M.; Hing, Z.A.; Kanga, P.; et al. Eµ-TCL1xMyc: A Novel Mouse Model for Concurrent CLL and B-Cell Lymphoma. Clin. Cancer Res. 2019, 25, 6260–6273. [CrossRef]
102. Young, R.M.; Hardy, I.R.; Clarke, R.L.; Lundy, N.; Pine, P.; Turner, B.C.; Potter, T.A.; Refaeli, Y. Mouse Models of Non-Hodgkin Lymphoma Reveal Syk as an Important Therapeutic Target. Blood 2009, 113, 2508–2516. [CrossRef]
103. García-Ramírez, I.; Tadros, S.; González-Herrero, I.; Martín-Lorenzo, A.; Rodríguez-Hernández, G.; Moore, D.; Ruiz-Roca, L.; Blanco, O.; Alonso-López, D.; Rivas, J.D.L.; et al. Crebbp Loss Cooperates with Bcl2 Overexpression to Promote Lymphoma in Mice. Blood 2017, 129, 2645–2666. [CrossRef]
104. Zhang, J.; Domínguez-Sola, D.; Hussein, S.; Lee, J.-E.; Holmes, A.B.; Bansal, M.; Vlasveskova, S.; Mo, T.; Tang, H.; Basso, K.; et al. Disruption of KMT2D Perturbs Germinal Center B Cell Development and Promotes Lymphomagenesis. Nat. Med. 2015, 21, 1190–1198. [CrossRef]
105. Béguelin, W.; Popovic, R.; Teater, M.; Jiang, Y.; Bunting, K.L.; Rosen, M.; Shen, H.; Yang, S.N.; Wang, L.; Exponda, T.; et al. EZH2 Is Required for Germline Center Formation and Somatic EZH2 Mutations Promote Lymphoid Transformation. Cancer Cell 2013, 23, 677–692. [CrossRef]
106. Knittel, G.; Liedgens, P.; Korovkina, D.; Seeger, J.M.; Al-Baldawi, Y.; Al-Maari, M.; Fritz, C.; Vlantis, K.; Bezhanova, S.; Scheel, A.H.; et al. B-Cell-Specific Conditional Expression of Myd88p.L252P Leads to the Development of Diffuse Large B-Cell Lymphoma in Mice. Blood 2016, 127, 2372–2374. [CrossRef]
107. Calado, D.P.; Zhang, B.; Srinivasan, L.; Sasaki, Y.; Seagal, J.; Unitt, C.; Rodig, S.; Kutor, J.; Tarakhovsky, A.; Schmidt-Supprian, M.; et al. Constitutive Canonical NF-κB Activation Cooperates with Disruption of BLIMP1 in the Pathogenesis of Activated B-Cell like Diffuse Large B-Cell Lymphoma. Cancer Cell 2010, 18, 580–589. [CrossRef]
108. Illidge, T.J.; Honeychurch, J.; Howatt, W.; Ross, F.; Wilkins, B.; Cragg, M. A New in Vivo and in Vitro B Cell Lymphoma Model, Pi-BCL1. Cancer Biother. Radiopharm. 2000, 15, 571–580. [CrossRef]
109. Timmerman, J.M.; Caspar, C.B.; Lambert, S.L.; Syrengelas, A.D.; Levy, R. Idiotype-Encoding Recombinant Adenoviruses Provide Protective Immunity against Murine B-Cell Lymphomas. Blood 2001, 97, 1370–1377. [CrossRef] [PubMed]
110. Chaise, C.; Itti, E.; Petegnief, Y.; Wirquin, E.; Copie-Bergman, C.; Farect, J.-P.; Delfau-Larue, M.-H.; Meignan, M.; Talbot, J.-N.; Molinier-Frenkel, V. [F-18]-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography as a Tool for Early Detection of Immunotherapy Response in a Murine B Cell Lymphoma Model. *Cancer Immunol. Immunother.* 2007, 56, 1163–1171. [CrossRef] [PubMed]

111. Palmieri, C.; Falcone, C.; Iaccino, E.; Tuccillo, F.M.; Gaspari, M.; Trimboli, F.; De Laurentis, A.; Luberto, L.; Pontoriero, M.; Pisano, A.; et al. In Vivo Targeting and Growth Inhibition of the A20 Murine B-Cell Lymphoma by an Idiotype-Specific Peptide Binder. *Blood* 2010, 116, 226–238. [CrossRef] [PubMed]

112. Curti, A.; Pandolfi, S.; Valsasina, B.; Alqui, M.; Isidori, A.; Ferri, E.; Salvestrini, V.; Bonanno, G.; Rutella, S.; Durelli, I.; et al. Modulation of Tryptophan Catabolism by Human Leukemic Cells Results in the Conversion of CD25- into CD25+ T Regulatory Cells. *Blood* 2007, 109, 2871–2877. [CrossRef] [PubMed]

113. Yan, J.-S.; Chen, X.-Y.; Li, W.-P.; Yang, Y.; Song, Z.-L. Establishing SCID Mouse Models of B-Cell Non-Hodgkin’s Lymphoma. *Ai Zhong* 2009, 28, 181–183.

114. Ackler, S.; Xiao, Y.; Mitten, M.J.; Foster, K.; Oleksijew, A.; Refici, M.; Schlessinger, S.; Wang, B.; Chemburkar, S.R.; Bauch, J.; et al. ABT-263 and Rapamycin Act Cooperatively to Kill Lymphoma Cells In Vitro and In Vivo. *Mol. Cancer Ther.* 2008, 7, 3265–3274. [CrossRef]

115. Jiang, Y.; Ortega-Molina, A.; Geng, H.; Ying, H.-Y.; Hatzi, K.; Parsa, S.; McNally, D.; Wang, L.; Doane, A.S.; Agirre, X.; et al. CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas. *Cancer Discov.* 2017, 7, 53–58. [CrossRef]

116. Flümann, R.; Nieper, P.; Reinhardt, H.C.; Knittel, G. New Murine Models of Aggressive Lymphoma. *Blood Cancer Discov.* 2015, 9, 788–798. [CrossRef] [PubMed]

117. Yabe, D.; Fukuda, H.; Aoki, M.; Yamada, S.; Takebayashi, S.; Shinkura, R.; Yamamoto, N.; Honjo, T. Generation of a Conditional Knockout Allele for Mammalian Spn Protein Mint/SHARP. *Genesis* 2007, 45, 300–306. [CrossRef] [PubMed]

118. Hampel, F.; Ehrenberg, S.; Hojer, C.; Draeseke, A.; Marschall-Schröter, G.; Kühn, R.; Mack, B.; Giès, O.; Vahl, C.J.; Schmidt-Supprian, M.; et al. CD19-Independent Instruction of Murine Marginal Zone B-Cell Development by Constitutive Notch2 Signaling. *Blood* 2011, 118, 6321–6331. [CrossRef] [PubMed]

119. Ennishi, D.; Takata, K.; B.; Curti, A.; Pandolfi, S.; Valzasina, B.; Aluigi, M.; Isidori, A.; Ferri, E.; Salvestrini, V.; Bonanno, G.; Rutella, S.; Durelli, I.; et al. Induced by Intratumoral Injection of a TLR9 Ligand in Mouse Lymphoma. *Immunol. Cell Biol.* 2018, 96, 53–63. [CrossRef] [PubMed]

120. Ortega-Molina, A.; Boss, I.W.; Canela, A.; Pan, H.; Jiang, Y.; Zhao, C.; Jiang, M.; Hu, D.; Agirre, X.; et al. The Histone Lysine Methyltransferase KMT2D Sustains a Gene Expression Program That Represses B Cell Lymphoma Development. *Blood* 2014, 123, 300–306. [CrossRef] [PubMed]

121. Ennishi, D.; Takata, K.; B.; Curti, A.; Pandolfi, S.; Valzasina, B.; Aluigi, M.; Isidori, A.; Ferri, E.; Salvestrini, V.; Bonanno, G.; Rutella, S.; Durelli, I.; et al. Induced by Intratumoral Injection of a TLR9 Ligand in Mouse Lymphoma. *Immunol. Cell Biol.* 2018, 96, 53–63. [CrossRef] [PubMed]

122. Day, C.-P.; Merlino, G.; Van Dyke, T. Preclinical Mouse Cancer Models: A Maze of Opportunities and Challenges. *Methods* 2017, 121–122, 55–67. [CrossRef]

123. Talmadge, J.E.; Singh, R.K.; Fidler, I.J.; Raz, A. Murine Models to Evaluate Novel and Conventional Therapeutic Strategies for Cancer. *Am. J. Pathol.* 2007, 170, 793–804. [CrossRef]

124. Wefers, B.; Bashir, S.; Rossius, J.; Wurst, W.; Kühn, R. Gene Editing in Mouse Zygotes Using the CRISPR/Cas9 System. *Nat. Biotechnol.* 2014, 32, 941–946. [CrossRef] [PubMed]

125. Heckl, D.; Kowalczyk, M.S.; Yudovich, D.; Belizaire, R.; Puram, R.V.; McConkey, M.E.; Thielke, A.; Aker, J.; Regev, A.; Ebert, B.L. Generation of Mouse Models of Myeloid Malignancy with Combinatorial Genetic Lesions Using CRISPR-Cas9 Genome Editing. *Nat. Biotechnol.* 2014, 32, 941–946. [CrossRef] [PubMed]

126. Di Rosso, M.E.; Sterle, H.A.; Cremaschi, G.A.; Genaro, A.M. Beneficial Effect of Fluoxetine and Sertraline on Chronic Stress-Induced Tumor Growth and Cell Dissemination in a Mouse Model of lymphoma: Crucial Role of Antitumor Immunity. *Front. Immunol.* 2018, 9, 1341. [CrossRef] [PubMed]

127. Di Rosso, M.E.; Sterle, H.A.; Cremaschi, G.A.; Genaro, A.M. Beneficial Effect of Fluoxetine and Sertraline on Chronic Stress-Induced Tumor Growth and Cell Dissemination in a Mouse Model of lymphoma: Crucial Role of Antitumor Immunity. *Front. Immunol.* 2018, 9, 1341. [CrossRef] [PubMed]

128. Sagiv-Barfi, I.; Kohrt, H.E.; Burckhardt, L.; Czerwinski, D.K.; Levy, R. Ibrutinib Enhances the Antitumor Immune Response Induced by Intratumoral Injection of a TLR9 Ligand in Mouse Lymphoma. *Blood* 2015, 125, 2079–2086. [CrossRef]

129. Passineau, M.J.; Siegel, G.P.; Everts, M.; Pereboev, A.; Jilala, D.; Wang, M.; Zhu, Z.B.; Park, S.K.; Curiel, D.T.; Nelson, G.M. The Natural History of a Novel, Systemic, Disseminated Model of Syngeneic Mouse B-Cell Lymphoma. *Leuk. Lymphoma* 2005, 46, 1627–1638. [CrossRef]

130. Chapuy, B.; Cheng, H.; Watahiki, A.; Ducar, M.D.; Tan, Y.; Chen, L.; Roemer, M.G.M.; Ouyang, J.; Christie, A.L.; Zhang, L.; et al. Diffuse Large B-Cell Lymphoma Patient-Derived Xenograft Models Capture the Molecular and Biological Heterogeneity of the Disease. *Blood* 2016, 127, 2103–2123. [CrossRef]
132. DiFranco, K.M.; Johnson-Farley, N.; Bertino, J.R.; Elson, D.; Vega, B.A.; Belinka, B.A.; Kachlany, S.C. LFA-1-Targeting Leukotoxin (LtxA®; Leukothera®) Causes Lymphoma Tumor Regression in a Humanized Mouse Model and Requires Caspase-8 and Fas to Kill Malignant Lympocytes. Leuk. Res. 2015, 39, 649–656. [CrossRef]

133. Zhang, L.; Nomie, K.; Zhang, H.; Bell, T.; Pham, L.; Kadri, S.; Segal, J.; Li, S.; Zhou, S.; Santos, D.; et al. B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy. Clin. Cancer Res. 2017, 23, 4212–4223. [CrossRef] [PubMed]

134. Brassard, J.A.; Lutolf, M.P. Engineering Stem Cell Self-Organization to Build Better Organoids. Nat. Rev. Drug Discov. 2015, 14, 910–919. [CrossRef] [PubMed]

135. 2D and 3D Cell Culture—A Comparison of Different Types of Cancer Cell Cultures. Leukemia 2011, 25, 4212–4223. [CrossRef] [PubMed]

136. Alizadeh, A.A.; Gentles, A.J.; Alencar, A.J.; Liu, C.L.; Kohrt, H.E.; Houtou, R.; Goldstein, M.J.; Zhao, S.; Natkunam, Y.; Advani, R.H.; et al. Prediction of Survival in Diffuse Large B-Cell Lymphoma Based on the Expression of 2 Genes Reflecting Tumor and Microenvironment. Blood 2011, 118, 1350–1358. [CrossRef]

137. Gentles, A.J.; Newman, A.M.; Liu, C.L.; Bratman, S.V.; Feng, W.; Kim, D.; Nair, V.S.; Xu, Y.; Khuong, A.; Hoang, C.D.; et al. The Prognostic Landscape of Genes and Infiltrating Immune Cells across Human Cancers. Nat. Med. 2015, 21, 938–945. [CrossRef]

138. Pizzi, M.; Boi, M.; Bertoni, F.; Inghirami, G. Emerging Therapies Provide New Opportunities to Reshape the Multifaceted Interactions between the Immune System and Lymphoma Cells. Leukemia 2016, 30, 1805–1815. [CrossRef] [PubMed]

139. Kappalczyńska, M.; Kolenda, T.; Przybyła, W.; Zajaczkowska, M.; Teresiak, A.; Filas, V.; Bliźniak, R.; Łuczewski, Ł.; Lamperska, K. 2D and 3D Cell Culture—A Comparison of Different Types of Cancer Cell Cultures. Arch. Med. Sci. 2018, 14, 910–919. [CrossRef] [PubMed]

140. Kappalczyńska, M.; Kolenda, T.; Przybyła, W.; Zajaczkowska, M.; Teresiak, A.; Filas, V.; Bliźniak, R.; Łuczewski, Ł.; Lamperska, K. 2D and 3D Cell Culture—A Comparison of Different Types of Cancer Cell Cultures. Arch. Med. Sci. 2018, 14, 910–919. [CrossRef] [PubMed]

141. Kim, J.W.; Ho, W.J.; Wu, B.M. The Role of the 3D Environment in Hypoxia-Induced Drug and Apoptosis Resistance. Anticancer Res. 2011, 31, 3237–3245.

142. Katt, M.E.; Placone, A.L.; Wong, A.D.; Xu, Z.S.; Searson, P.C. In Vitro Tumor Models: Advantages, Disadvantages, Variables, and Selecting the Right Platform. Front. Bioeng. Biotechnol. 2016, 4, 12. [CrossRef] [PubMed]

143. Esch, E.W.; Bahinski, A.; Huh, D. Organs-on-Chips at the Frontiers of Drug Discovery. Nat. Rev. Drug Discov. 2015, 14, 248–260. [CrossRef] [PubMed]

144. DiFranco, K.M.; Johnson-Farley, N.; Bertino, J.R.; Elson, D.; Vega, B.A.; Belinka, B.A.; Kachlany, S.C. LFA-1-Targeting Leukotoxin (LtxA®; Leukothera®) Causes Lymphoma Tumor Regression in a Humanized Mouse Model and Requires Caspase-8 and Fas to Kill Malignant Lympocytes. Leuk. Res. 2015, 39, 649–656. [CrossRef]

145. Kappalczyńska, M.; Kolenda, T.; Przybyła, W.; Zajaczkowska, M.; Teresiak, A.; Filas, V.; Bliźniak, R.; Łuczewski, Ł.; Lamperska, K. 2D and 3D Cell Culture—A Comparison of Different Types of Cancer Cell Cultures. Arch. Med. Sci. 2018, 14, 910–919. [CrossRef] [PubMed]

146. Kappalczyńska, M.; Kolenda, T.; Przybyła, W.; Zajaczkowska, M.; Teresiak, A.; Filas, V.; Bliźniak, R.; Łuczewski, Ł.; Lamperska, K. 2D and 3D Cell Culture—A Comparison of Different Types of Cancer Cell Cultures. Arch. Med. Sci. 2018, 14, 910–919. [CrossRef] [PubMed]

147. Pizzi, M.; Boi, M.; Bertoni, F.; Inghirami, G. Emerging Therapies Provide New Opportunities to Reshape the Multifaceted Interactions between the Immune System and Lymphoma Cells. Leukemia 2016, 30, 1805–1815. [CrossRef] [PubMed]

148. Kappalczyńska, M.; Kolenda, T.; Przybyła, W.; Zajaczkowska, M.; Teresiak, A.; Filas, V.; Bliźniak, R.; Łuczewski, Ł.; Lamperska, K. 2D and 3D Cell Culture—A Comparison of Different Types of Cancer Cell Cultures. Arch. Med. Sci. 2018, 14, 910–919. [CrossRef] [PubMed]

149. Kim, J.W.; Ho, W.J.; Wu, B.M. The Role of the 3D Environment in Hypoxia-Induced Drug and Apoptosis Resistance. Anticancer Res. 2011, 31, 3237–3245.

150. Katt, M.E.; Placone, A.L.; Wong, A.D.; Xu, Z.S.; Searson, P.C. In Vitro Tumor Models: Advantages, Disadvantages, Variables, and Selecting the Right Platform. Front. Bioeng. Biotechnol. 2016, 4, 12. [CrossRef] [PubMed]

151. Esch, E.W.; Bahinski, A.; Huh, D. Organs-on-Chips at the Frontiers of Drug Discovery. Nat. Rev. Drug Discov. 2015, 14, 248–260. [CrossRef] [PubMed]

152. Han, K.; Pierce, S.E.; Li, A.; Spees, K.; Anderson, G.R.; Seoane, J.A.; Lo, Y.-H.; Dubreuil, M.; Olivas, M.; Kamber, R.A.; et al. CRISPR Screens in Cancer Spheroids Identify 3D Growth-Specific Vulnerabilities. Nature 2020, 580, 136–141. [CrossRef]

153. Sabbachandani, P.; Sarkar, S.; Mckenney, S.; Ravi, D.; Evens, A.M.; Konry, T. Microfluidic Assembly of Hydrogel-Based Immunogenic Tumor Spheroids for Evaluation of Anticancer Therapies and Biomarker Release. J. Control. Release 2019, 295, 21–30. [CrossRef]

154. Tian, Y.F.; Ahn, H.; Schneider, R.S.; Yang, S.N.; Roman-Gonzalez, L.; Melnick, A.M.; Cerchietti, L.; Singh, A. Integrin-Specific Hydrogels as Adaptable Tumor Organoids for Malignant B and T Cells. Biomaterials 2015, 73, 110–119. [CrossRef] [PubMed]

155. Rosenthal, N.; Brown, S. The Mouse Ascending: Perspectives for Human-Disease Models. Nat. Cell Biol. 2007, 9, 993–999. [CrossRef] [PubMed]

156. Mcllman, I.; Coukos, G.; Dranoff, G. Cancer Immunotherapy Comes of Age. Nature 2011, 480, 480–489. [CrossRef] [PubMed]

157. Aboulkheyr Es, H.; Montazeri, L.; Aref, A.R.; Vosough, M.; Baharvand, H. Personalized Cancer Medicine: An Organoid Approach. Trends Biotechnol. 2018, 36, 358–371. [CrossRef] [PubMed]
158. Béguelin, W.; Rivas, M.A.; Calvo Fernández, M.T.; Teater, M.; Purwada, A.; Redmond, D.; Shen, H.; Challman, M.F.; Elemento, O.; Singh, A.; et al. EZH2 Enables Germinal Centre Formation through Epigenetic Silencing of CDKN1A and an Rb-E2F1 Feedback Loop. Nat. Commun. 2017, 8, 877. [CrossRef]

159. Scholze, H.; Stephenson, R.E.; Reynolds, R.; Shah, S.; Puri, R.; Butler, S.D.; Trujillo-Alonso, V.; Teater, M.R.; van Besien, H.; Gibbs-Curtis, D.; et al. Combined EZH2 and Bcl-2 Inhibitors as Precision Therapy for Genetically Defined DLBCL Subtypes. Blood Adv. 2020, 4, 5226–5231. [CrossRef]

160. Fontan Gabas, L.; Goldstein, R.L.; Casalena, G.; Durant, M.; Teater, M.R.; Wilson, J.; Phillip, J.M.; Xia, M.; Shah, S.; Us, I.; et al. Identification of MALT1 Feedback Mechanisms Enables Rational Design of Potent Anti-Lymphoma Regimens for ABC-DLBCL. Blood 2020. [CrossRef]

161. Mannino, R.G.; Pradhan, P.; Roy, K.; Lam, W.A. 3D In Vitro Microvascular Model-Based Lymphoma Model. Methods Cell Biol. 2018, 146, 149–158. [CrossRef] [PubMed]

162. Junttila, M.R.; de Sauvage, F.J. Influence of Tumour Micro-Environment Heterogeneity on Therapeutic Response. Nature 2013, 501, 346–354. [CrossRef] [PubMed]

163. Takahashi, T. Organoids for Drug Discovery and Personalized Medicine. Annu. Rev. Pharmacol. Toxicol. 2019, 59, 447–462. [CrossRef] [PubMed]